Biogen Inc. (BIIB) Stock Score, Valuation & Financial Research
Biogen Inc. is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 32/100.
Quick answer for BIIB
Biogen Inc. currently has a Wall Street Score of 32/100. The stored market price is $217.15. Its financial score is 27/100. Its valuation score is 10/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Biogen Inc. does
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions li
BIIB financial snapshot
- Wall Street Score:
- 32/100
- Current price:
- $217.15
- Market capitalization:
- $32.08B
- Revenue:
- $9.95B
- Net income:
- $835.1M
- Free cash flow:
- $2.05B
- Cash:
- $1.28B
- Total debt:
- $8.36B
- EPS:
- 5.68
- P/E ratio:
- 38.2x
- Financial score:
- 27/100
- Valuation score:
- 10/100
- Revenue score:
- 11/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $2.05B, showing positive cash generation.
- The balance sheet shows $1.28B of cash versus $8.36B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: BIIB increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 10/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 27/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BIIB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.